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BACKGROUND: Little is known about the effect of participating in a colorectal cancer (CRC) screening programme on quality of life
(QOL), neither for participants with a negative nor for those with a positive test result. These findings, however, are important to
evaluate the impact of CRC screening.
METHODS: Participants from CRC screening trials were sent a questionnaire, which included validated measures on generic
health-related QOL, generic anxiety and screen-specific anxiety. Both faecal immunochemical test (FIT) and flexible sigmoidoscopy
(FS) participants, either with negative or positive test results, were addressed.
RESULTS: The response rate was 73% (1289 out of 1772) for FIT and 78% (536 out of 689) for FS participants, with mean ages varying
from 63–66 years. Positive FIT participants had worse physical (PCS-12, 47.1 vs 48.3, P¼ 0.02), but equal mental QOL scores
(MCS-12, 51.1 vs 51.6, P¼ 0.26). Positive and negative FS participants had similar QOL scores. Both FIT and FS participants with a
positive test result reported more screen-specific anxiety than negative FIT and FS participants. Positive and negative FS participants
had similar generic anxiety scores.
CONCLUSION: Our findings indicate that the burden of participating in CRC screening may be limited. Conducting a prospective study
to confirm these results is recommended.
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Worldwide, colorectal cancer (CRC) is the third most common
malignancy in males and the second most common in females (Jemal
et al, 2011). Colorectal cancer is the second cause of cancer-related
death in developed countries (Center et al, 2009; Jemal et al, 2011).
Five-year survival is over 90% when the disease is detected in an
early stage (stage I), compared with o10% for CRC with distant
metastases (stage IV). Population-based screening programs can
reduce CRC-related mortality by early detection and treatment of
CRC, but also by removal of premalignant lesions (adenoma)
(Mandel et al, 1993; Nicholson et al, 2005; Atkin et al, 2010).
Different CRC screening tests are available. These mainly
include faecal occult blood tests (FOBTs) and endoscopy, in
particular flexible sigmoidoscopy (FS) and colonoscopy. The latter
techniques enable visualisation of a part or of the entire colon.
However, these techniques are more invasive and more expensive
than FOBTs. Randomised controlled trials (RCTs) showed that
screening by means of FOBTs followed by colonoscopy if
indicated, reduces CRC-related mortality by 15–33% (Hewitson
et al, 2008; Pizzo et al, 2011). More recently, a RCT with a median
follow-up of 11.2 years from the UK showed that once-only FS
screening between 55 and 64 years of age can substantially reduce
colorectal cancer incidence and mortality (Atkin et al, 2010),
although another similar FS screening RCT did not observe a
mortality reduction after 7 years (Hoff et al, 2009).
Several Western countries have started or are considering
introduction of FOBT or FS screening. In both FOBT- and
FS-based screening programs, participants with a positive test are
referred for colonoscopy. In the decision on the introduction of a
population-based CRC screening programme, benefits such as
life-years gained due to early detection and subsequent early
treatment need to be outweighed against the burden of screening,
such as the anxiety and distress due to participation, both with
respect to the invitation and the test itself, as well as related to
positive test results, whether truly or false positive. Anxiety in a
screened population has previously been assessed for PAP smear
results in cervical screening, where scores for generic and screen-
specific anxiety were significantly higher in women with an
abnormal smear (Korfage et al, 2010). The only two studies that
investigated quality of life (QOL) effects in CRC screening showed
that screening did not appear to have adverse emotional effects in
the longer term (44 weeks) (Taylor et al, 2004; Taupin et al, 2006).
These studies were focussed on colonoscopy- and FS-based
screening. More information on QOL among participants in CRC
screening is needed.
In this study, we aimed to assess QOL of participants in a
FOBT- and FS-based CRC screening programme. The main
research question of the study was whether QOL differed in
participants with a positive test result compared with participants
with a negative test result, and whether QOL differed between
participants with true- and false-positive results. Furthermore, we
evaluated whether differences in QOL were related to age, gender
and social economic status. These findings can help to determine
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the impact of CRC screening, so quality of life and anxiety of a
CRC screening programme can be clarified.
MATERIALS AND METHODS
Study population
Between November 2006 and December 2010, two Dutch popula-
tion-based randomised CRC screening trials (CORERO-I and –II
trial) were conducted in the southwest of the Netherlands with a
target population of approximately 350 000 inhabitants. Average-
risk individuals, aged between 50 and 74 years, were invited and if
eligible included for FS or successive rounds of faecal immuno-
chemical test (FIT) screening (Hol et al, 2010; van Roon et al,
2012). Within this cohort we conducted a retrospective observa-
tional study between December 2010 and April 2011. We addressed
all participants of the CORERO-I or -II trial who had a positive
screening test and a random sample of participants with a negative
screening test (reference group).
An FIT value of X50 ngml 1 was considered positive. A
positive FS was defined as a sigmoidoscopy that revealed a polyp
with a diameter X10mm; an adenoma with X25% villous
component or high-grade dysplasia; serrated adenoma; X3
adenomas; X20 hyperplastic polyps; or CRC (Hol et al, 2010).
Positive participants were referred for colonoscopy. All positive
FIT participants were addressed and an equal number of controls
was randomly selected (negative FIT participants). All positive FS
participants were addressed as well. Because of power considera-
tions we randomly selected twice as many controls, that is negative
FS participants.
All selected screen participants were addressed with a ques-
tionnaire (see below for further details), an informed consent form
and an accompanying letter, asking them to complete and return
the questionnaire. A reminder was sent after 4 weeks to all non-
respondents. It was clarified in the letter that the choice to not
participate in this questionnaire study would not have any
consequences for health care or follow-up. The data on the
amount of time that had elapsed between participation in the CRC
screening programme and completion of the questionnaire were
obtained through the regional screening organisation. Information
on gender, age, marital status, income, education, country of birth
and comorbidity was obtained through the questionnaire. Educa-
tional level was classified as low (primary school or lower technical
education), intermediate or high (college/university degree).
Content of the questionnaire
The questionnaire included the following validated measures.
Generic HRQoL was assessed through the 12-item Short-Form
Health Survey (SF-12) and the EuroQol classification (EQ-5D). The
SF-12 consists of 12 items in the physical and mental domains.
These 12 items are used to construct physical and mental summary
measures (PCS-12 and MCS-12; scoring range from 0–100)
(Gandek et al, 1998). Age- and sex-adjusted SF-12 norm scores
are available from Statistics Netherlands (2010).
The EQ-5D classification consists of five items (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression).
Classification scores can be linked to a utility score with 0
indicating ‘death’ and 1 indicating ‘full health’ (Dolan, 1997). The
EQ-5D is complemented by a visual analogue scale on current
health, the valuation of own health, which is anchored at the lower
end (0) by ‘worst imaginable health state’ and at the upper end
(100) by ‘best imaginable health state’.
Generic anxiety was assessed by the STAI-6, a validated short
version of the State Trait Anxiety Inventory, containing six items
on, for example, feeling at ease or upset. Scores range from 20
(almost never anxious) to 80 (almost always anxious), with higher
scores correlating with greater anxiety. A STAI-score of over 44
defines an individual as highly anxious (Millar et al, 1995). To
measure the screen-specific anxiety (that is the psychological
impact of a positive CRC screening test) we used the Psychological
Consequences Questionnaire (PCQ). The PCQ measures the
consequences of screening on three dimensions, that is emotional,
physical and social functioning. Ratings for symptoms within each
dimension vary from 0 (not at all) to 3 (quite a lot of time). The
added ratings indicate the level of dysfunction with higher scores
indicating more dysfunction. As the subscales are highly
correlated, we also report an overall PCQ score (score range
0–36). We used the Dutch version as adapted by Rijnsburger et al
(2006).
Perceived risk of developing CRC was assessed through a Cancer
Worry Scale (CWS) (Gramling et al, 2007). The CWS consists of
items such as ‘During the last week, how often have you thought
about your own chances of developing cancer?’ and; ‘During the
last week, how often have thoughts about getting cancer affected
your mood?’. For each question, participants were given the
following four response items: ‘Not at all or Rarely’, ‘Sometimes’,
‘Often’ and ‘Almost all the time’.
Furthermore, the questionnaire included items on how people
make decisions regarding their health in general and how people
look back at the screening procedure as a whole. This last topic
contained questions on whether people would participate in the
CRC screening programme again and whether participants would
recommend participating to a friend or relative.
Statistical analyses
In accordance with the guidelines missing items in the STAI and
PCQ scales were imputed by participants’ own average score if at
least 50% of these items had been completed (Ware et al, 1993). To
assess non-response bias we compared gender and age of the
respondents with those of the non-respondents. Differences
between the groups in background variables, in health-related
QOL, generic and screen-specific anxiety scores, worries regarding
cancer and in general attitude towards screening were assessed
using Mann–Whitney U tests for continuous variables and w2 tests
for categorical ones.
We tested the relationship between generic anxiety and screen-
specific anxiety scores on the one hand and the time period that
had elapsed since the screening on the other hand, by comparing
scores of participants who had a screening test 4–12 months before
completion of the questionnaire vs 12–24 months vs424 months.
Furthermore, we examined whether QOL scores differed between
FIT participants with a true and false-positive test result.
Statistical analyses were performed using SPSS for Windows,
version 15. A P-value o0.05 (referring to two-sided statistical
tests) was considered significant. The ethics review committee of
the Erasmus MC, University Medical Center Rotterdam, approved
the research protocol (MEC-2010-411).
RESULTS
Response and respondent characteristics
All participants of the CORERO-I and -II trial who had either a
positive FIT result (cutoff 50 ngml 1, n¼ 857) or a positive FS
(n¼ 227) were sent a questionnaire (n¼ 1084). A questionnaire
was also sent to a randomly selected group of 1377 participants
with a negative screening test (i.e., a negative FIT (915 out a total of
7825 participants) or a negative FS (462 out of a total of 1971
participants)). All FS participants participated in the CRC screen-
ing programme 3–5 years before filling out the questionnaire, with
a mean interval time of 44 months. The FIT participants
participated in the CRC screening programme varying from 5
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years to 4 months before filling out the questionnaire, with a mean
interval time of 15 months and 26 months, respectively, for
negative and positive FIT participants (data not shown).
Response rates for FIT and FS participants varied between
73 and 82% (Figure 1). The respondents’ characteristics are shown
in Table 1. Participants with a positive FIT result were more often
male (60.8% vs 46.5%, Po0.001) and were older than participants
with a negative FIT result (mean age 65.5 vs 63.0 years, Po0.001).
A similar pattern was seen in FS participants: more were males
(64.2% vs 57.3% males, P¼ 0.125) and were older of age (mean age
66.1 vs 63.9 years, Po0.001) in the group with a positive test result.
No differences were observed with respect to education, income,
marital status and country of birth between those with a positive
and negative test result. Compared with non-responders, respon-
ders in the FIT group were more often male (53% vs 42%,
Po0.001). No differences in age existed between these two groups.
There were no differences regarding gender distribution and age
between FS responders and non-responders (data not shown).
Quality of life scores
Generic QOL SF-12 scores regarding physical health were
significantly lower in FIT participants with a positive test result
than in those with a negative result, indicating worse functioning
in this group (Table 2). Furthermore, positive FIT participants had
significantly worse EQ-5D scores and rated their own health worse
than participants with a negative test result. The QOL scores
did not differ between positive and negative FS participants.
When comparing the SF-12 scores to the age-adjusted norm scores
for the Dutch population, we found that for both FIT and FS
participants of X 65 years, the PCS-12 scores were higher,
indicating better physical functioning in participants than in the
general population (CBS StatLine). The FIT participants under
the age of 65 showed worse physical functioning compared with
the general population. No difference was seen for FS participants
under the age of 65. The mental health-related QOL scores were
lower than those in the general population, indicating worse
mental functioning in our participants (CBS StatLine).
Genereric anxiety and screen-specific anxiety The STAI-6 score
was significantly lower in FIT participants with a positive test
result, indicating less generic anxiety in these participants
compared with negative FIT participants (Table 2). The STAI-6
scores did not differ between positive and negative FS participants.
Total PCQ scores were significantly higher in FIT and FS
participants with a positive test result, indicating more screen-
specific anxiety in these participants compared with participants
with a negative test result (Table 2).
No statistically significant differences were found in generic
anxiety, screen-specific anxiety and QOL scores between negative
FIT participants and positive FIT participants who underwent a
colonoscopy 4–12 months vs 12–24 months vs424 months before
completion of the questionnaire (Tables 3A and B). The QOL
scores, generic anxiety and screen-specific anxiety did not differ
between positive FIT participants who subsequently had a negative
(false-positive FIT) vs a positive (true-positive FIT) colonoscopy
(Table 4).
Overall acceptance
The vast majority of FIT participants would encourage friends
and/or relatives to undergo screening (negative FIT participants:
95%, positive FIT participants: 92%; P¼ 0.060) and was willing to
attend a successive screening round (negative FIT participants:
99%, positive FIT participants 92%; Po0.001) (Figure 2). The same
positive attitude towards screening was found in FS participants,
who reported similarly high scores for encouraging friends and/or
relatives to undergo screening (negative FS participants: 97.4%,
positive FS participants: 99.4%; P¼ 0.024) and willingness to
attend a successive screening round (negative FS participants:
92.7%, positive FS participants: 95.6%; P¼ 0.253).
DISCUSSION
This study examined the QOL of participants in a CRC screening
programme. The response rate was high. Participants with
Participants of FIT
915/7825 Randomly selected and 
sent a questionnaire
664 (72.6%) Responders
Male gender: 46.5%*
Age (mean): 63.0 years*
625 (73.0%) responders
Male gender: 60.8%*
Age (mean): 65.5 years*
1 Incomplete 1 Incomplete
663 Included in analysis 624 Included in analysis
7825 Negative (FIT) participants
857 Sent a questionnaire
879 Positive (FIT) participants
Participants of FS
462/1971 Randomly selected and 
sent a questionnaire
349 (75.5%) Responders
Male gender: 57.3%*
Age (mean): 63.9 years
187 (82.4%) Responders
Male gender: 64.2%*
Age (mean): 66.1 years
2 Incomplete 0 Incomplete
347 Included in analysis 187 Included in analysis
1971 Negative (FS) participants
227 Sent a questionnaire
228 Positive (FS) participants
857 Underwent colonoscopy
22 Refused colonoscopy
227 Underwent colonoscopy
1 Refused colonoscopy
*: statistical significant difference (P<0.05) between responders and non-responders within the same screening strategy  
Figure 1 Flowchart of study responders.
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a positive FIT had slightly worse QOL scores than participants with
a negative FIT test. Furthermore, no significant differences were
seen in QOL scores between positive FIT participants with either a
negative or a positive colonoscopy. No differences were found in
QOL scores between positive and negative FS participants. Both
FIT and FS participants with a positive test result had higher PCQ
scores than negative participants, indicating more screen-specific
anxiety in these groups. Overall, these findings may indicate that
the burden of participating in a CRC screening programme is
limited.
Few studies investigated QOL in relation to CRC screening.
Taupin et al (2006) performed a study among primary
colonoscopy screening participants. Participants completed the
Short-Form (SF-36) QOL assessment at baseline and at a mean of
39 days after colonoscopy. Baseline QOL measures were similar to
those of a matched general population sample. Thirty percent of all
participants reported positive changes in mental health and vitality
after colonoscopy, irrespective of the outcome. Unfortunately,
long-term effects on QOL were not assessed. The PLCO Trial
(Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)
investigated QOL among screening FS participants (Taylor et al,
2004). The FS participants were interviewed by telephone at
different time intervals (at baseline, shortly after notification and
nine months after notification of screening results). Control-arm
Table 1 Background characteristics of responders by type of CRC screening
Faecal immunochemical test Flexible sigmoidoscopy
Negative test
result (n¼663)
Positive test
result (n¼624) P-value
Negative test
result (n¼ 347)
Positive test
result (n¼ 187) P-value
Age (years)
Mean (s.d.) 63.0 (±6.1) 65.5 (±6.4) o0.001 63.9 (±6.3) 66.1 (±6.7) o0.001
Male gender (%) 308 (46.5) 380 (60.8) o0.001 199 (57.3) 120 (64.2) 0.13
Education (%) 0.15 0.65
Low 211 (32.3) 209 (34.4) 106 (31.1) 61 (33.2)
Medium 273 (41.8) 267 (43.9) 142 (41.7) 69 (37.5)
High 169 (25.8) 129 (21.2) 92 (26.9) 52 (28.2)
Income (%) 0.08 0.82
o22.125 euros 178 (31.1) 174 (32.6) 86 (28.7) 52 (31.4)
22.125–44.250 euros 248 (43.3) 237 (44.4) 130 (43.3) 71 (42.8)
444.250 euros 147 (25.7) 123 (23.1) 84 (28.0) 43 (26.0)
Marital status (%) 0.13 0.18
Married/cohabiting 571 (87.2) 523 (84.4) 305 (89.2) 154 (83.7)
Living alone 84 (12.8) 97 (15.7) 37 (10.8) 30 (16.3)
Country of birth (%) 0.85 0.41
The Netherlands 616 (93.5) 579 (94.3) 316 (92.4) 177 (95.2)
Abbreviation: CRC¼ colorectal cancer.
Table 2 Mean scale scores of responders with a negative and responders with a positive test result
Faecal immunochemical test Flexible sigmoidoscopy
Negative test
result (n¼ 663)
Positive test
result (n¼ 624) P-value
Negative test
result (n¼347)
Positive test
result (n¼ 187) P-value
Generic HRQoL
SF-12 (0–100)a
Physical health (PCS-12) 48.3 (8.9) 47.1 (9.4) 0.02 48.1 (8.8) 47.0 (9.3) 0.20
Mental health (MCS-12) 51.6 (8.9) 51.1 (9.2) 0.26 52.0 (8.5) 50.3 (9.6) 0.11
EuroQoLa
EQ-5D (0–1) 0.85 (0.19) 0.82 (0.20) 0.02 0.85 (0.17) 0.80 (0.24) 0.13
Rating of own health (0–100) 77.3 (16.7) 74.5 (16.9) o0.001 76.5 (16.6) 72.8 (18.6) 0.01
Generic anxietya
STAI-6 (20–80) 43.8 (5.2) 43.3 (5.2) 0.03 42.6 (4.8) 43.3 (4.5) 0.25
Screen-specific anxietya
PCQ
Emotional scale (0–15) 1.03 (2.1) 1.79 (2.7) o0.001 1.29 (2.2) 1.81 (2.7) 0.02
Physical scale (0–12) 0.73 (1.6) 1.11 (1.9) o0.001 0.87 (1.6) 1.22 (2.2) 0.12
Social scale (0–9) 0.46 (1.2) 0.78 (1.5) o0.001 0.61 (1.2) 0.78 (1.6) 0.56
Total score (0–36) 2.22 (4.3) 3.67 (5.4) o0.001 2.77 (4.4) 3.81 (5.8) 0.03
Abbreviations: EQ-5D¼ European quality of Life-5 dimensions; EuroQoL¼ European quality of life; HRQoL¼ health-related quality of life; MCS-12¼Mental Component
Health-related Quality of Life Score; PCQ¼ Psychological Consequences Questionnaire; PCS-12¼ Physical Component Health-related Quality of Life Scores; SF-12¼Medical
Outcomes Study 12-Item Short-form Health Survey; STAI-6¼ Six-item State Trait Anxiety Inventory. aFor SF-12 and EuroQoL a higher score indicates better health. For Generic
anxiety and screen-specific anxiety a higher score indicates more anxiety.
CRC screening program
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participants (no screening) completed a baseline and 1-year
follow-up assessment. After 9 months FS participants with
abnormal screening results did not show higher levels of intrusive
thoughts about cancer than those with normal results (P¼ 0.096;
odds ratio (OR)¼ 1.9, 95% confidence interval (CI)¼ 0.89–4.2).
These results are in line with our study, where we found similar
QOL scores among negative and positive FS participants.
In our study, we found that both FIT and FS participants with a
positive test result showed significantly more screen-specific
anxiety than participants with a negative test result. To indicate
clinical relevance we used the minimal important difference
(MID), defined as the smallest change in a patient-reported
outcome that is perceived by patients as beneficial or that would
result in a change of treatment. The MID was operationalised as a
Table 3B Mean scale scores of responders with a positive test result, for the whole group and per time period passed between participation in the
screening programme and filling out the questionnaire
Positive faecal immunochemical test
Positive test result (n¼ 624) 4–12 Months 13–24 Months 25 Months or more P-valuea
Generic HRQoL
SF-12 (0–100)b
Physical health (PCS-12) 47.1 (9.4) 47.4 (10.1) 46.7 (10.4) 47.1 (8.7) 0.61
Mental health (MCS-12) 51.1 (9.2) 52.5 (8.5) 50.8 (10.0) 50.8 (9.1) 0.26
EuroQoLb
EQ-5D (0–1) 0.82 (0.20) 0.84 (0.20) 0.81 (0.23) 0.82 (0.19) 0.28
Rating of own health (0–100) 74.5 (16.9) 77.4 (13.1) 72.9 (18.9) 74.5 (16.6) 0.32
Generic anxietyb
STAI-6 (20–80) 43.3 (5.2) 42.8 (5.4) 43.4 (4.8) 43.5 (5.3) 0.53
Screen-specific anxietyb
PCQ
Emotional scale (0–15) 1.79 (2.7) 1.69 (2.6) 1.79 (2.6) 1.81 (2.8) 0.81
Physical scale (0–12) 1.11 (1.9) 1.05 (1.9) 1.09 (1.7) 1.12 (2.0) 0.86
Social scale (0–9) 0.78 (1.5) 0.79 (1.6) 0.83 (1.5) 0.75 (1.5) 0.72
Total score (0–36) 3.67 (5.4) 3.54 (5.5) 3.72 (5.1) 3.67 (5.5) 0.85
Abbreviations: EQ-5D¼ European Quality of Life-5 Dimensions; EuroQoL¼ European Quality of Life; HRQoL: Health-related Quality of Life; PCQ¼ Psychological
Consequences Questionnaire; PCS-12¼ Physical Component Health-related Quality of Life Scores; MCS-12¼Mental Component Health-related Quality of Life Score;
SF-12¼Medical Outcomes Study 12-Item Short-form Health Survey; STAI-6¼ Six-item State Trait Anxiety Inventory. aThe P-value indicates the significance level of differences
in observed scores between groups that participated in the CRC screening programme 4–12 months, 13–24 months or X25 months previously. bFor SF-12 and EuroQoL a
higher score indicates better health. For generic anxiety and screen-specific anxiety a higher score indicates more anxiety.
Table 3A Mean scale scores of responders with a negative test result, for the whole group and per time period passed between participation in the
screening programme and filling out the questionnaire
Negative faecal immunochemical test
Negative test
result (n¼663)
4–12
Months
13–24
Months
25 Months
or more
P-valuea
Generic HRQoL
SF-12 (0–100)b
Physical health (PCS-12) 48.3 (8.9) 48.9 (9.0) 47.6 (9.0) 50.5 (6.3) 0.05
Mental health (MCS-12) 51.6 (8.9) 51.7 (8.5) 51.6 (9.2) 50.4 (9.3) 0.68
EuroQoLb
EQ-5D (0–1) 0.85 (0.19) 0.85 (0.17) 0.84 (0.20) 0.89 (0.17) 0.28
Rating of own health (0–100) 77.3 (16.7) 78.9 (14.9) 75.5 (18.3) 82.0 (11.3) 0.05
Generic anxietyb
STAI-6 (20–80) 43.8 (5.2) 43.7 (5.4) 43.9 (5.0) 44.0 (6.0) 0.85
Screen-specific anxietyb
PCQ
Emotional scale (0–15) 1.03 (2.1) 1.00 (2.1) 1.06 (2.1) 0.84 (2.0) 0.30
Physical scale (0–12) 0.73 (1.6) 0.64 (1.4) 0.84 (1.7) 0.38 (1.0) 0.16
Social scale (0–9) 0.46 (1.2) 0.43 (1.2) 0.50 (1.2) 0.41 (1.6) 0.44
Total score (0–36) 2.22 (4.3) 2.07 (4.1) 2.40 (4.5) 1.63 (4.3) 0.36
Abbreviations: EQ-5D¼ European Quality of Life-5 Dimensions; EuroQoL¼ European Quality of Life; HRQoL: Health-related Quality of Life; PCQ¼ Psychological
Consequences Questionnaire; PCS-12¼ Physical Component Health-related Quality of Life Scores; MCS-12¼Mental Component Health-related Quality of Life Score; SF-
12¼Medical Outcomes Study 12-Item Short-form Health Survey; STAI-6¼ Six-item State Trait Anxiety Inventory. aThe P-Value indicates the significance level of differences in
observed scores between groups that participated in the CRC screening programme 4–12 months, 13–24 months orX25 months previously. bFor SF-12 and EuroQoL a higher
score indicates better health for generic anxiety and screen-specific anxiety a higher score indicates more anxiety.
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difference of at least half a s.d. (Norman et al, 2003). Although
some differences in QOL scores were statistifically significant, all
differences in QOL scores between negative and positive FIT and
FS participants were rather small and none of them exceeded the
MID. These are therefore not clinically relevant. Two other studies
among participants in a FOBT-screening programme and one FS
screening study, assessing worries associated with CRC screening,
showed that most of the participants did not experience an
increase in anxiety (Lindholm et al, 1997; Thiis-Evensen et al,
1999; Parker et al, 2002). Control groups consisted of an age- and
gender-matched group not invited for screening (Thiis-Evensen
et al, 1999; Parker et al, 2002) and persons who had received the
invitation letter but had not attended the screening programme
(Lindholm et al, 1997). Furthermore, participants did not develop
adverse psychological effects 17 months after screening (Lindholm
et al, 1997; Parker et al, 2002).
Literature on CRC screening shows that even in subjects with a
false-positive test result, screening for CRC has no adverse effect
on anxiety on the long-term (Parker et al, 2002; Brasso et al, 2010).
Population-based screening studies regarding prostate and breast
cancer found similar results (Sutton et al, 1995; Essink-Bot et al,
1998). Apparently, a false-positive test result does not negatively
affect participants’ QOL. These findings are in accordance with our
study, as QOL scores were similar in positive FIT participants with
either a negative or a positive colonoscopy. Possible explanations
for these mainly positive effects of CRC screening in participants
with a true-positive result could be that, although participants are
worried because of the possibility of having colorectal cancer, they
are either simultaneously relieved that they found out on time and
will be screened regularly to prevent colorectal cancer, or they are
reassured because they soon underwent treatment. In case of a
false-positive result, we hypothesised that participants are relieved
that no abnormalities were found during further investigations.
In our study, we addressed large numbers of participants in a
CRC screening programme. Both participants with a positive and
negative test result who underwent either FOBT or FS were
included. Another strength is that the response rate to the
questionnaire was high. Furthermore, validated measures were
used to assess QOL and we were able to compose a questionnaire
that enables to understand the impact of screening on participants’
QOL. A review of instruments to measure the QOL of participants
in a CRC screening programme reinforced the importance of such
a questionnaire (Pizzo et al, 2011). We unfortunately have no
information on QOL of non-participants, and we have no
information on QOL, nor psychological or physical, before FIT
or FS testing. These baseline values are essential to make a correct
comparison, and to correct the effect of factors such as age
(screen-positive participants were older than screen-negative
participants). Participants in a screening study might not reflect
the general population and might react differently. We did,
however, look at mean SF-12 scores in the general Dutch
population. Furthermore, we don’t have data on QOL and anxiety
of the entire screening process (e.g., after performing the screening
test, while waiting for the test result, after colonoscopy, and so on).
Because the majority of responders were of Caucasian ethnicity,
our results cannot be extrapolated to a non-Caucasian population.
Further studies in a non-Caucasian population are therefore
needed.
In summary, this retrospective questionnaire survey on QOL
among participants of a FIT or FS CRC screening programme
showed slightly worse QOL scores among positive FIT participants
compared with FIT negative participants. Compared with the
general Dutch population, mental health-related QOL scores were
lower among all participants. Screen-specific anxiety was
significantly higher among both positive FIT and FS participants,
indicating that a positive test result has a negative impact on
participants’ emotional well-being, although differences were small
Table 4 Mean scale scores of responders with a positive test result (FIT)
by result of the colonoscopy
Negative
colonoscopy
after positive
FIT
(n¼ 288)
Positive
colonoscopy
after
positive FIT
(n¼ 184) P-value
Generic HRQoL
SF-12 (0–100)a
Physical health (PCS-12) 46.7 (9.7) 47.6 (9.1) 0.34
Mental health (MCS-12) 50.8 (9.1) 51.4 (9.5) 0.29
EuroQoLa
EQ-5D (0–1) 0.81 (0.21) 0.82 (0.22) 0.14
Rating of own health (0–100) 74.2 (16.7) 75.7 (15.9) 0.29
Generic anxietya
STAI-6 (20–80) 43.5 (4.9) 43.5 (5.4) 1.00
Screen-specific anxietya
PCQ
Emotional scale (0–15) 1.74 (2.7) 1.76 (2.7) 0.82
Physical scale (0–12) 1.06 (1.8) 1.09 (2.0) 0.72
Social scale (0–9) 3.60 (5.3) 0.80 (1.7) 0.18
Total score (0–36) 0.81 (1.4) 3.65 (5.7) 0.97
Abbreviations: EQ-5D¼ European Quality of Life-5 Dimensions; EuroQoL¼
European Quality of Life; FIT¼ faecal immunochemical test; HRQoL¼Health-
related Quality of Life; MCS-12¼Mental Component Health-related Quality of Life
Score; PCQ¼ Psychological Consequences Questionnaire; PCS-12¼ Physical
Component Health-related Quality of Life Scores; SF-12¼Medical Outcomes Study
12-Item Short-form Health Survey; STAI-6¼ Six-item State Trait Anxiety Inventory.
aFor SF-12 and EuroQoL a higher score indicates better health. For generic anxiety
and screen-specific anxiety a higher score indicates more anxiety.
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Figure 2 Scores on the advice subjects would give and willingness to return. Using a 5-point Likert scale (0–100 scale): scores on the advice subjects
would give others to participate in screening and willingness of screenees to return for successive screening rounds.
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and not clinically relevant. With respect to cost-effectiveness
analyses that aim to assess quality-adjusted life-years lost or
gained by screening, our results suggest that the impact of FIT and
FS screening on experienced QOL after the screening process will
be modest. A prospective study needs to be conducted, where
participants receive questionnaires at different time points during
the entire screening process. Only this way, we will fully be able to
evaluate the impact of screening on QOL and anxiety and
anticipate on possible negative side-effects.
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